Prognostic significance of subcarinal station in non-small cell lung cancer with T1-3 N2 disease

Thoracic and Cardiovascular Surgeon

Volumn 54, Issue 1, 2006, Pages 42-46

  Iwasaki, A ^a   Shirakusa, T ^a   Miyoshi, T ^a   Hamada, T ^a   Enatsu, S ^a   Maekawa, S ^a   Hiratsuka, M ^a  

^a FUKUOKA UNIVERSITY   (Japan)

Author keywords

N2 disease; Non small cell lung cancer; Subcarinal lymph node

Indexed keywords

ADULT; AGED; CANCER STAGING; DIAGNOSTIC VALUE; FEMALE; HUMAN; LOBECTOMY; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LYMPH NODE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; STERNUM; SUBCARINAL LYMPH NODE; SURVIVAL RATE; SURVIVAL TIME;

ADENOCARCINOMA; AGED; ANALYSIS OF VARIANCE; CARCINOMA, ADENOSQUAMOUS; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PULMONARY SURGICAL PROCEDURES; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 32544434968     PISSN: 01716425     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-865828     Document Type: Review

References (19)

1. Martini N, Flehniger BJ, Zaman MB, Beattie EJ. Results of resection in non-oat cell carcinoma of the lung with mediastinal lymph-node metastases. Ann Surg 1983; 198: 386-397
2. Ishida T, Yano T, Maeda K, Kaneko S, Tateishi M, Sugimachi K. Surgery for lymphadenectomy in lung cancer three centimeters or less in diameter. Ann Thorac Surg 1990; 50: 708-713
3. Naruke T. Significance of lymph node metastasis in lung cancer. Semin Thorac Cardiovasc Surg 1993; 5: 210-218
4. Keller SM, Vangel MG, Wagner H, Schiller JH, Herskovic A, Komaki R, Marks RS, Perry MC, Livingston RB, Johnson DH. Eastern Cooperative Oncology Group. Prolonged survival in patients with resected non-small cell lung cancer and single-level N2 disease. J Thorac Cardiovasc Surg 2004; 128: 130-137
5. Misthos P, Sepsas E, Athanassiadi K, Kakaris S, Skottis I. Skip metastases: analysis of their clinical significance and prognosis in the IIIA stage of non-small cell lung cancer. Eur J Cardiothorac Surg 2004; 25: 502-508
6. Brueno R, Richards WG, Swanson SJ, Jaklitsch MT, Lukanich JM, Mentzer SJ, Sugarbaker DJ. Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival. Ann Thorac Surg 2000; 70: 1826-1831
7. Mathisen DJ, Wain JC, Wright C, Choi N, Carey R, Hilgenberg A, Grossbard M, Lynch T, Grillo H. Assessment of preoperative accelerated radiotherapy and chemotherapy in stage IIIa (N2) non-small cell lung cancer. J Thorac Cardiovasc Surg 1996; 111: 123-133
8. Naruke T, Suemasu K, Ishikawa S. Lymph node mapping and curability at various levels of metastasis in resected lung cancer. J Thorac Cardiovasc Surg 1978; 76: 832-839
9. Inoue M, Sawabata N, Takeda S, Ohta M, Ohno Y, Maeda H. Results of surgical intervention for p-stage IIIA (N2) non-small cell lung cancer: acceptable prognosis predicted by complete resection in patients with single N2 disease with primary tumor in the upper lobe. J Thorac Cardiovasc Surg 2004; 127: 1100-1106
10. Ichinose Y, Kato H, Koike T, Tsuchiya R, Fujisawa T, Shimizu N, Watanabe Y, Mitsudomi T, Yoshimura M, Tsuboi M. Japanese Clinical Oncology Group. Completely resected stage IIIA non-small cell lung cancer: the significance of primary tumor location and N2 station. J Thorac Cardiovasc Surg 2001; 122: 803-808
11. Tanaka F, Takenaka K, Oyanagi H, Fujinaga T, Otake Y, Yanagihara K, Ito H, Wada H. Skip mediastinal nodal metastases in non-small cell lung cancer. Eur J Cardiothorac Surg 2004; 25: 1114-1120
12. Prenzel KL, Monig SP, Sinning JM, Baldus SE, Gustshow CA, Grass G, Schneider PM, Holscher AH. Role of skip metastasis to mediastinal lymph nodes in non-small cell lung cancer. J Surg Oncol 2003; 82: 256-260
13. Halter G, Buck AK, Schirrmeister H, Aksoy E, Liewald F, Glatting G, Neumaier B, Muhling B, Nussle-Kugele K, Hetzet M. Sunder-Plassmann L, Reske SN. Lymph node staging in lung cancer using [18 F]FDG-PET. Thorac Cardiovasc Surg 2004; 52: 96-101
14. Luketich JD, Friedman DM, Meltzer CC, Belani CP, Townsend DW, Christie NA, Weigel TL. The role of positron emission tomography in evaluating mediastinal lymph node metastases in non-small-cell lung cancer. Clin Lung Cancer 2001; 2: 229-233
15. Cerfolio RJ, Ojha B, Bryant AS, Bass CS, Bartalucci AA, Mountz JM. The role of FDG-PET scan in staging patients with non small cell carcinoma. Ann Thorac Surg 2003; 76: 861-866
16. Annema JT, Hoekstra OS, Smit EF, Veselic M, Versteegh MI, Rabe KF. Towards a minimally invasive staging strategy in NSCLC: analysis of PET positive mediastinal lesions by EUS-FNA. Lung Cancer 2004; 44: 53-60
17. Prenzel KL, Baldus SE, Monig SP, Tack D, Sinning JM, Gutschow CA, Grass G, Schnider PM, Dienes HP, Holscher AH. Skip metastasis in nonsmall cell lung carcinoma. Cancer 2004; 100: 1909-1917
18. Fujimoto J, Toyoki H, Sato E, Sakaguchi H, Tamaya T. Clinical implication of expression of vascular endothelial growth factor-C in metastatic lymph nodes of uterine cervical cancers. Br J Cancer 2004; 91: 466-469
19. Tamura M, Ohta Y. Serum vascular endothelial growth factor-C level in patients with primary non small cell lung carcinoma: a possible diagnostic tool for lymph node metastasis. Cancer 2003; 98: 1217-1222